Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02134574

Prospective Cohort With Hemopathy in Languedoc-Roussillon

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematologic Malignancy Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hematology department - UHMontpellier Saint éloi

Montpellier, France

Location status: Recruiting

Location contact

GUILLAUME CARTRON

PRINCIPAL_INVESTIGATOR

Valerie ROUILLE

CONTACT

[email protected]

About this study

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18
  • Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
  • Having signed an informed consent
  • Affiliated with a social security scheme

Exclusion criteria

  • Minor or major protected
  • Patients who have received treatment for hematological pathology

Treatment and study plan

hematologic malignancy

Biological

hematologic malignancy with a sampling of blood

Other names: hematologic malignancy with a sampling of blood

Primary outcomes

  1. Survival with 2 years

    Time frame: 2 years

    Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30

Secondary outcomes

  1. Survival with 5 years

    Time frame: 5 years

    Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30

  2. Survival with 10 years

    Time frame: 10 years

    Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30

Study contacts

Contact information is provided by the study sponsor or research team.

Valerie ROUILLE

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon

Acronym: HemoDiag

Important dates

Study start
2014
Primary completion
2033
Study completion
2033
First posted
May 9, 2014
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.